Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars ...

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully ...

Biocon has raised ₹4,150 crore via a Qualified Institutions Placement (QIP) process, issuing over 112 million equity shares.

Bengaluru: Biocon Limited has successfully concluded a Rs 4,150 crore (approximately USD 460 million) equity fundraise ...

Biocon raises ₹4,150 crore through QIP to acquire Mylan's stake in Biocon Biologics and repay associated debt.

Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the USFDA for its generic Everolimus tablets to treat tuberous sclerosis complex. Available in 2 mg, 3 mg, and 5 mg, the drug is ...

The board of Biocon has approved the issue of 11.26 crore equity shares of face value of ₹5 each to eligible institutions.